CKD 846
Alternative Names: CKD-846Latest Information Update: 09 Nov 2023
At a glance
- Originator Chong Kun Dang
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Benign prostatic hyperplasia
Most Recent Events
- 01 Nov 2023 Chong Kun Dang Pharmaceutical plans a phase I trial for Benign prostate hypertrophy (In volunteers) in South Korea (NCT06110923)
- 19 Apr 2023 Preclinical trials in Benign prostatic hyperplasia in South Korea (unspecified route), prior to April 2023 (Chong Kun Dang pharmaceuticals pipeline, April 2023)